Next Article in Journal
Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
Previous Article in Journal
Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses Than Seen in the Eosinophilic Subtype
Previous Article in Special Issue
Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
Open AccessReview

Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells

1
Center for Gender-Specific Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy
2
Institute of Translational Pharmacology, CNR, 00131 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(10), 1491; https://doi.org/10.3390/cancers11101491
Received: 13 September 2019 / Revised: 26 September 2019 / Accepted: 27 September 2019 / Published: 3 October 2019
(This article belongs to the Special Issue Immunotherapy, Tumor Microenvironment and Survival Signaling)
Colorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neoplastic cells, including immune cells. Several immune dysfunctions were described in CRC patients at different disease stages. Many studies underline the role of microbiota, obesity-related inflammation, diet and host reactive cells, including dendritic cells (DC), in CRC pathogenesis. Here, we focused on DC, the main cells linking innate and adaptive anti-cancer immunity. Variations in the number and phenotype of circulating and tumor-infiltrating DC have been found in CRC patients and correlated with disease stages and progression. A critical review of DC-based clinical studies and of recent advances in cancer immunotherapy leads to consider new strategies for combining DC vaccination strategies with check-point inhibitors, thus opening perspectives for a more effective management of this neoplastic disease. View Full-Text
Keywords: colorectal cancer; dendritic cells; immunotherapy; pathogenesis; risk factors colorectal cancer; dendritic cells; immunotherapy; pathogenesis; risk factors
Show Figures

Figure 1

MDPI and ACS Style

Gessani, S.; Belardelli, F. Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells. Cancers 2019, 11, 1491.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop